This article is more than 5 years old. Information may no longer be current.
Janssen seeks approval for sirukumab in European Union
Click Here to Manage Email Alerts
Janssen-Cilag International NV announced it has submitted a marketing authorization application to the European Medicines Agency for the approval of sirukumab to treat moderately to severely active rheumatoid arthritis in adults.
“At Janssen, we are committed to continued innovation in the field of rheumatoid arthritis through new therapeutic options, like sirukumab, that address the medical needs of people living with moderately to severely active rheumatoid arthritis,” Newman Yeilding, MD, head of the Immunology Development at Janssen Research and Development LLC, said in a company press release. “We look forward to collaborating with the European health authorities with the goal of bringing sirukumab to patients living with rheumatoid arthritis who may benefit from this new biologic therapy.”
According to the release, Janssen included data from the phase 3 SIRROUND clinical development program with its submission.
Reference: